Early Administration of Tocilizumab (Toci) for the...

Cytotherapy 2019 / 05 Vol. 21; Iss. 5

Early Administration of Tocilizumab (Toci) for the Prevention of Grade 4 Cytokine Release Syndrome (CRS) after CD19-directed CAR T-cell Therapy (CTL019)

Kadauke, S., Maude, S., Gladney, W., Motley, L., Shenoy, V., Callahan, C., Baniewicz, D., Teachey, D.T., Grupp, S., DiNofia, A.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
21
Journal:
Cytotherapy
DOI:
10.1016/j.jcyt.2019.04.009
Date:
May, 2019
File:
PDF, 532 KB
2019
Conversion to is in progress
Conversion to is failed